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health record based process to routinely assess and manage car-
diovascular disease (CVD) risk. METHODS: This project was
pilot tested in one Geisinger Clinic using EpiCare’s® EHR
system. Five computerized procedures were tested during routine
encounters to: 1) Deploy an automated protocol to identify
patients meeting criteria for CVD risk assessment; 2) determine
data elements missing to assess heart attack risk; 3) automati-
cally consent and order lab and patient self-reported risk ques-
tionnaires to assess risk; 4) activate a modiﬁed Framingham
CVD formula to calculate individual patient risk; and 5) engage
patients at moderate to high risk to review risk factors and deﬁne
goals. RESULTS: Over a 12-month period, 1610 patients were
eligible for screening, all of whom were missing data on one or
more CVD risk factors. Of these, orders for labs and question-
naire were placed for 27%; of these, 93% completed some or all
measures and 86% of those asked completed the online risk
assessment questionnaires. Using a modiﬁed Framingham risk-
scoring algorithm, 36% patients who were fully assessed, were
at moderate or high risk of a heart attack and were scheduled to
set goals to reduce their risk. Almost half of these patients com-
pleted their goal setting module. Goals were ﬁled back to the
EHR as a reference for monitoring patient progress. CONCLU-
SIONS: This preliminary test of a new model for CVD risk man-
agement suggests that automated protocols based on the EHR
can be used to routinely identify, assess and manage cardiovas-
cular disease risk. Primary care physicians can use EHR based
processes to improve patient management.
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OBJECTIVES: Non-achievement of combined optimal lipid
values (OLVs; LDL-C, HDL-C, and triglyceride [TG]) is associ-
ated with a 45% increase in cardiovascular events. Multiple lipid
abnormalities may require combination therapy, however sparse
data are available comparing marketed combination products
(extended release niacin/lovastatin [ERN/L] and simvastatin/eze-
timibe [S/E]). We modeled OLV attainment with ERN/L, S/E, and
components within a managed care (MCO) database.
METHODS: Patients were selected from a 2.1 million record
database based on: lipid panel between 1/1/00 and 12/31/01, no
concomitant lipid therapy, and continuous eligibility for 24
months. Initial lipid values and cardiovascular risk status (deter-
mined by ICD-9/CPT codes, prescription records) for each
patient was identiﬁed, and treatment effects were modeled using
product labeling at maximum doses. OLVs were based upon
NCEP ATP-III, AHA Women’s guidelines, or ADA guidelines.
RESULTS: We analyzed 44,351 patients; 50% male, age 65 + 13
years, and baseline lipids: LDL-C 131 + 35mg/dL, HDL-C 48 +
15mg/dL, TG 159 + 77mg/dL. At baseline, 10.1% achieved
OLVs which increased with ERN/L 56.1%, S/E 48.4%, ERN
36.4%, L 35.6%, S 42.3%, and E 18.4% (chi-square p < 0.05
all vs baseline; ERN/L vs S/E, ERN, and L; S/E vs S and E). In
2° prevention (N = 20,948), OLV increased from 8.2% to 51.1%
ERN/L, 50.4% S/E, 27.9% ERN, 31.8% L, 45.0% S, 17.7% E
(p < 0.05 for vs baseline; ERN/L vs ERN and L; S/E vs S and E).
In diabetes (N = 8,164), OLV increased from 7.4% to 50.5%
ERN/L, 46.0% S/E, 28.2% ERN, 30.2% L, 41.9% S, 16.4% E
(p < 0.05 all vs baseline; ERN/L vs S/E, ERN, and L; S/E vs E),
with similar results in 1° prevention (N = 23,403). CONCLU-
SIONS: In this MCO population, OLVs were best achieved with
ERN/L versus S/E. In a broad sprectrum of risk populations,
ERN/L achieved signiﬁcantly greater OLVs than each of it’s indi-
vidual components, in contrast to S/E.
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OBJECTIVE: This prospective, observational study evaluates the
medication utilization patterns and cost of treatment of patients
treated for myocardial infarction (MI) at a government institu-
tion in Kerala, India. METHODS: Patients with a diagnosis of
MI and received streptokinase (SK) therapy are enrolled into the
study. The following data is collected: demographics, clinical
outcomes, laboratory results, ECG resolution, drug utilization
parameters, and cost data from a patient perspective. The cost
of drug therapy for each patient is calculated utilizing the
Current Index of Medical Specialties 2004. Logistic regression
univariate analysis is conducted to determine the association
between outcome and treatment factors with p < 0.05.
RESULTS: One hundred ﬁfty patients are enrolled. The mean
age is 59.1 years and 77% of the patients are male. The average
pain to treatment period for SK therapy is 4.69 hours, while the
average door to treatment period is 79.9 minutes. A total of
34.7% of the patients experience a post SK ECG resolution
above 70% and in hospital mortality is 12.67%. Logistic regres-
sion results indicate that greater than 70% resolution on ECG
is associated with shorter treatment window period, non ante-
rior infarct, dyslipidemia, lower CPK-1 level, and lower rate of
mortality. Increased mortality is associated with heart block,
hypotension, low ECG resolution, arrhythmias, low ejection
fraction, CHF, and less use of beta blockers, nitrates, ace
inhibitors, and atorvastatin. The average cost of care to the
patient is Rs 5600.15 (SD Rs 13762.87). The average cost to the
hospital for free medicines is Rs 2629.06 (SD Rs 1515.22).
Patients who had at least 70% ECG resolution have an average
cost of Rs 4090.28, while patients who had less have an average
cost of Rs 5539.98. CONCLUSION: Management of myocar-
dial infarction utilizing SK appears to improve clinical outcomes
and be cost-effective in a government setting in Kerala, India.
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OUTCOMES OF CONGESTIVE HEART FAILURE INPATIENTS
TREATED WITH NESIRITIDE
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OBJETIVES: Nesiritide is indicated for the intravenous treat-
ment of patients with acutely decompensated heart failure who
have dyspnea at rest or with minimal activity. In a recent study
it was recommended the drug be used only for inpatient settings.
We investigated effectiveness of Nesiritide in a group of Con-
gestive Heart Failure (CHF) inpatients using Solucient’s
ACTracker inpatient database. METHODS: A cohort of 28,332
Congestive Heart Failure patients discharged from 21 hospitals
from 4/2003 to 6/2005 was selected with 7,668 patients treated
with nesiritide as study group and a comparison group of 20,664
non Nesiritide treated patients. Chi-Square and t tests were used
to compare the two groups for mortality rate and hospital length
of stay (LOS) respectively. Conditional Logistic regression was
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used for mortality and ANCOVA was used for LOS with con-
founding factors adjusted in the models. Adjusted factors
included patient demographics, hospital characteristics (bed size,
region, teaching and PCI annual volume), co-morbid conditions
(chronic obstructive pulmonary disease, peripheral vascular
disease, diabetes mellitus, malignancy, acute renal failure) and
severity. RESULTS: Patients treated with nesiritide had signiﬁ-
cantly higher average hospital charges vs. not treated ($48,493
vs. $27,315, t = 22.94, p < 0.001). No better outcomes were
observed in nesiritide treated patients measured by LOS (10.03
vs 6.54, t = 22.71, p < 0.001) and mortality (Chi = 2.94, p =
0.086). The increased LOS (p < 0.001) in nesiritide treated group
were supported by ANCOVA model with control for covariates
including severity, mortality and payor type. Further analysis in
mortality by using conditional logistic regression showed con-
sistent results. CONCLUSIONS: Patients treated with nesiritide
are associated with higher costs, LOS and were not found to
obtain a cost effective therapy during their hospital stay. To
conﬁrm the ﬁnding, further study in inpatient settings and more
efﬁcient methods e.g. propensity score analysis are suggested to
better control for inﬂuencing factors.
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CARDIOVASCULAR RISK PREDICTED BY ADHERENCE TO
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OBJECTIVES: To determine the impact of adherence to statin
therapy on the incidence of cardiovascular events in a Medicaid
managed care population. METHODS: Retrospective database
analysis of Maryland Medicaid medical and pharmacy claims for
the period January 1, 2001–December 31, 2003. Inclusion cri-
teria: Continuously enrolled patients older than 18 years who
had at least one prescription claim for any of the statins. Exclu-
sion criteria (to obtain incident cohort): Patients who had at least
a claim before July 1st, 2002. Non-adherence was deﬁned as a
failure to reﬁll a prescription claim. Logistic regression models
were built to determine the association of drug adherence
adjusted for age, gender, race, comorbidities (based on Charlson
Comorbidity Index) with cardiovascular events. RESULTS: Out
of a total of 1997 patients, most were females (61%), African
Americans (57%), and 60 years old or younger (70%). Based on
univariate analysis, persistent patients had a lower incidence of
cardiovascular events than non-persistent patients (19% vs.
32%), females a lower incidence than males (24% vs. 35%) and
African Americans a lower incidence than Caucasians (24% vs.
34%). In the logistic regression model adjusting for comorbidi-
ties and demographics, drug adherence (OR 0.460, 59% CI
0.357, 0.593), African American race (OR 0.596, 95%CI 0.485,
0.734), and male gender (OR 1.674, 95% CI 1.369, 2.047) were
signiﬁcantly associated with CV events. CONCLUSION: In this
Medicaid population of statin users, the incidence of cardiovas-
cular events is higher in males, Caucasians and in patients who
do not adhere to statin therapy. Risk management programs may
need to focus on drug adherence among statin users, as one of
the major modiﬁable factors to reduce cardiovascular events.
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OBJECTIVES: Achieving combined optimal lipid values (OLVs)
for LDL-C, HDL-C, and triglycerides (TG) is associated with
reduced cardiovascular events; however little is known about the
subsequent loss of OLV. This study evaluated the loss of OLV
and associated cardiovascular events in a managed care (MCO)
population. METHODS: Patients were selected from a 2.1
million record database based on: lipid panel between January
1, 2000 and December 1, 2001, no concomitant lipid therapy,
and continuous eligibility for 24 months. Patients were catego-
rized as 1°/2° prevention, male/female, and diabetes mellitus
(DM). Guidelines deﬁned OLVs: NCEP ATP III (1° and 2° pre-
vention, men), AHA (women), and ADA (DM). Combined OLV
achievement was determined, as were cardiovascular events
based on ICD-9/CPT codes. The association between loss of
combined OLV achievement and cardiovascular events was eval-
uated by multivariate logistic regression and calculated odds
ratios (OR). RESULTS: The study included 44,351 patients: 1°
prevention (23,403); 2° prevention (20,948); males (22,345);
females (22,006); and DM (8,164). Mean age was 64 ± 13 years,
with a follow-up of 30 ± 12 months. Baseline lipids (mg/dL):
total cholesterol 210 ± 40; LDL-C 131 ± 35; HDL-C 48 ± 14;
and, TG 159 ± 77. Baseline combined OLV was achieved in
8–13%, which increased to 17–21% during follow-up. There
were 10,899 cardiovascular events experienced in 6,722 patients.
Loss of combined OLV was associated with an increase in car-
diovascular events in the total population (OR 1.43, 95% CI,
1.30–1.57). Subgroups demonstrated a similar increase in events
(OR: 1.40 to 1.67; 95% CI, 1.28 to 1.88) except 1° prevention
(OR, 1.2; 95% CI, 1.0–1.3). CONCLUSION: Combined OLVs
were achieved by <25% of patients. Loss of combined OLV
achievement was associated with a signiﬁcant 40 to 67%
increase in cardiovascular event risk, excepting 1° prevention
patients. Maintaining combined OLV achievement has the poten-
tial to signiﬁcantly improve outcomes across a wide spectrum of
patients.
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PATIENT EDUCATION INITIATIVE IN A MANAGED CARE
SETTING
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OBJECTIVES: Adverse drug events (ADEs) associated with war-
farin therapy result in signiﬁcant morbidity, mortality, and eco-
nomic costs. Previous studies have demonstrated that ADEs are
associated with a Prothrombin Time (PT) or International Nor-
malized Ratio (INR) value outside of the accepted therapeutic
range. The purpose of this study is to evaluate the effectiveness
of a mail-based warfarin education program in improving
member PT/INR values and reducing ADEs and medical and
pharmacy costs in a managed care setting. METHODS: A total
of 1401 members initiated on warfarin therapy were random-
ized to an intervention or control group. The intervention group
received a series of six educational letters, which included infor-
mation about warfarin, the importance of PT/INR testing, signs
and symptoms of supra- and sub-therapeutic PT/INR values, and
a reminder to schedule physician appointments. Members were
followed for a mean of 341.5 days after initiation of warfarin.
